Lexaria Bioscience (CSE: LXX-NASDAQ: LEXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive to share details about the company’s three human clinical trials and two animal research trials. Bunka telling Proactive how these studies are going so far. The studies are using Lexaria’s DehydraTECH CBD for the treatment of hypertension and are being performed by third-party laboratories to ensure study objectivity.
Lexaria provides update on 5 studies focussed on DehydraTECH CBD as a treatment for hypertension
